FIG 3.

Distribution of tedizolid exposure in adolescents with versus without PCS abnormal hematology values in the phase 3 PN012 trial in adolescents.^a,b. AUC_{0–24h_last}, area under the concentration–time curve from 0 to 24 hours on the last dosing day; C_{max 0–24h_last}, maximum concentration of drug in plasma from 0 to 24 hours on the last dosing day; C_{min 0–24h_last}, minimum concentration of drug in plasma from 0 to 24 hours on the last dosing day; PCS, potentially clinically significant. ^aThe participant with C_max of >9 μg/ml had only one pharmacokinetic data point available to estimate tedizolid exposure. One participant had missing values and could not be evaluated. ^bThe participant with the highest predicted AUC_{0–24h_last} had very high tedizolid plasma concentrations that were mostly excluded as outliers. The AUC_{0–24h_last} for this participant was predicted based on a single concentration measurement after outlier exclusions and should therefore be interpreted with caution.